A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)
PHASE4CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
August 1, 2007
Primary Completion Date
June 1, 2009
Study Completion Date
June 1, 2009
Conditions
Hypertension
Interventions
DRUG
Losartan 50 mg / HCTZ 12.5 mg
Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
All Listed Sponsors
lead
Organon and Co
INDUSTRY
NCT01431508 - A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) | Biotech Hunter | Biotech Hunter